Korean drug firm signs record license deal

Published: 2013-09-30 06:57:00

Updated: 2013-09-30 06:57:00

Korean biopharmaceutical company Medytox said Thursday that it has signed a deal to exclusively license a neurotoxin to Procter & Gamble Pharmaceuticals (P&GP) that could be worth US$$362 million.

Under the deal, Allergan will pay Medytox an upfront payment of US$65 million and Medytox will gr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK